Oberlin Conservatory of Music
Natasha Tiffany, MD, is a hematology and oncology specialist based in Salem, Oregon, who is currently active in the development and management of the Salem Cancer Institute. Apart from her medical training, Natasha Tiffany, MD, is also a classically trained pianist who completed the piano program at the prestigious Oberlin Conservatory of Music.
The Ohio-based Oberlin Conservatory of Music is the oldest such institution in the US, and is noted for maintaining an outstanding reputation, consistently being cited as one of the best music schools in the country. Oberlin also initiated several innovations in music education,
Oberlin College and Conservatory is credited with being the birthplace of the double degree, whereby graduates leave with another concentration besides music. The double degree has become a prime consideration for high-achieving students to consider Oberlin. The program enables students with multiple talents and interests to satisfy more than one of them at the same time.
American Society of Clinical Oncology
Since 2004, Natasha Tiffany, MD, has worked as a physician for Hematology Oncology of Salem in Oregon. As a hematologist and oncologist, Natasha Tiffany, MD, takes care of patients daily and stays up-to-date with industry-wide changes by maintaining membership with the American Society of Clinical Oncology (ASCO).
Established in 1964, ASCO began as an organization dedicated to clinical oncology. ASCO hosts several annual networking opportunities, including conferences, seminars, and professional workshops.
One event hosted by ASCO is its annual meeting, with the 2016 meeting occurring June 3 through 7 at McCormick Place in Chicago, Illinois. Funded through the Conquer Cancer Foundation, this annual meeting typically brings in more than 30,000 oncology professionals from around the globe. Titled Collective Wisdom: The Future of Patient-Centered Care and Research, the 2016 event will cover topics such as clinical trial design, geriatric oncology, rapid learning systems, and genomics. Attendees will learn who the organization’s award recipients are, hear updates on the state of the society, and listen to the president’s address. In addition, the annual meeting will feature educational sessions, mentoring opportunities for fellows, and poster discussions.
A physician partner practicing in Salem, Oregon, Natasha Tiffany, MD, possesses more than two decades of medical experience. Handling oncology cases, Natasha Tiffany, MD, is knowledgeable of aromatase inhibitors, such as anastrozole.
Among the treatments available for female patients diagnosed with breast cancer is anastrozole. The drug caters to individuals who are past menopause as well as those who have received tamoxifen therapy that resulted in further disease progression. In particular, anastrozole can reduce the size of tumors by lowering a person’s blood estradiol concentration.
A doctor must prescribe anastrozole to a patient and offer instructions for consumption and dosage. The medicine can be taken with or without food, but only one dose is recommended at a time. A missed dose should be consumed as soon as possible. If the timeframe is nearing a next dose, the patient should skip the missed dose and then return to their normal schedule. A medical professional can give further information on the drug’s use and side effects.
A triple board-certified physician specializing in hematology and oncology, Natasha Tiffany, MD, serves as a partner and practicing physician at Hematology Oncology of Salem in Salem, Oregon. Natasha Tiffany, MD, and the medical staff at Hematology Oncology of Salem utilize the latest cancer treatments, therapies, and medications, including aromatase inhibitors.
Aromatase inhibitors are a newer class of drugs that are often used to treat breast cancer or prevent its recurrence following surgery in postmenopausal women. Drugs in this class, which include letrozole, anastrozole, and exemestane, work by inhibiting the action of aromatase, the enzyme responsible for converting androgen into estrogen. These drugs are particularly effective in treating estrogen receptor-positive (ER+) breast cancers because they reduce the amount of available estrogen, which these types of cancers need to grow.
Either used alone or in combination with other drugs, aromatase inhibitors have been shown to be an effective treatment for both early and metastatic or recurring ER+ breast cancer. These drugs are also often prescribed off-label to treat conditions such as infertility and endometriosis. While they tend to be milder than other cancer drugs, the most common side effects of aromatase inhibitors include joint pain or stiffness, hot flashes, and bone thinning.
Cancer treatments are rapidly evolving. Traditional chemotherapy targets rapidly replicating cells. This kills the cancer cells, but can also lead to side effects such as hair loss, nausea and vomiting because the hair cells and the cells lining the gastrointestinal tract also divide quickly.
In recent years, scientists have been designing targeted treatments that are designed to block pathways needed for cancer cells to replicate and survive. Many cancer cells have genetic mutations in them that drive tumor growth. If we can identify a driving mutation in a tumor, we can design treatments that shut down the pathway it uses to promote cell division and survival. This targeted approach often has fewer side effects than traditional chemotherapy.
This personalized cancer therapy is very promising. We are committed to providing our patients the most up to date and cutting edge treatments available. We may talk to you about doing genetic testing of your tumor to see if you might benefit from targeted therapy.
Currently, many of the targeted treatments are available only through clinical trials, but some are already available as standard of care. We can help you find the best treatment options for you. If you have questions about personalized cancer treatments, please talk to your oncologist.
Natasha Tiffany, MD, administers innovative cancer treatments, such as targeted therapy, through Hematology Oncology of Salem, LLP, in Salem, Oregon. In preparation for her career, she underwent fellowship training in modern cancer care through Oregon Health and Science University. Before deciding whether to pursue targeted cancer therapy, patients ought to consult with an experienced professional like Natasha Tiffany, MD.
A relatively new treatment method, targeted therapy encompasses those medications that hone in on and influence specific molecules that regulate the growth and overall survival of cancer cells. Such methods are distinct from traditional chemotherapy, which does damage to both healthy and malignant cells. Currently, there is a range of targeted therapies available, including those that rely on hormones to treat hormone-sensitive growths and those that trigger controlled cell death in tumors.
For an oncologist to consider targeted therapy as a possible option, the patient in question needs to have a cancer that matches the available therapies. This may require that patients undergo genetic testing to see if their tumor cells actually have the necessary molecules for the therapy to target.
A cum laude graduate of Oregon Health and Science University, Natasha Tiffany, M.D., practices with Hematology Oncology of Salem. She has a professional interest in breast cancer therapy and prescribes aromatase inhibitors such as anastrozole and letrozole in treating certain patients. A newer type of medication, aromatase inhibitors are used by postmenopausal women to halt harmful estrogen production by the aromatase enzyme.
Without the inhibitor, aromatase turns androgen into small amounts of estrogen, which in turn stimulates the growth of breast cancer cells that are hormone-receptor-positive. This treatment approach is distinct from drugs such as raloxifene and tamoxifen, which work by blocking the estrogen receptors. Several studies have compared aromatase inhibitors and tamoxifen. Breastcancer.org notes that aromatase inhibitors typically are recommended as the best hormonal treatment to begin with, particularly among early-stage breast cancer patients who have undergone surgery (and in some cases radiation therapy and chemotherapy). The reason is that aromatase inhibitors appear to have fewer serious side effects, and more benefits overall, than their tamoxifen counterparts.